Closing the 'Gross Gap': New Tech Targets Silent IV Infection Threat

MISSISSAUGA, Ontario – April 10, 2026 – In hospitals worldwide, the intravenous (IV) line is a lifeline, delivering critical fluids and medications. But this ubiquitous tool harbors a silent and deadly risk: contamination. A growing body of evidence suggests a critical vulnerability in patient care—a “gross gap” in protection at IV connection points that contributes to thousands of preventable, and often fatal, bloodstream infections each year.

This pressing issue is set to take center stage at the upcoming Infusion Nurses Society (INS) 2026 Annual Meeting in Louisville, Kentucky. There, medical technology firm Covalon Technologies Ltd. will highlight a new front in the war against hospital-acquired infections, focusing on the often-overlooked contamination of IV hubs and connectors.

The High Cost of a Hidden Danger

Catheter-Associated Blood Stream Infections (CABSIs) are one of the most serious complications in modern healthcare. According to global health data, these infections carry a staggering mortality rate of 12% to 25% and add an average of $46,000 to the cost of a single patient’s hospital stay. In the United States alone, an estimated 250,000 such infections occur annually, with a notable 65% spike in ICU rates observed during the recent pandemic, underscoring the persistent and evolving nature of the threat.

For years, infection control efforts have centered on sterile insertion techniques and protective dressings at the catheter entry site. However, vascular access expert Dr. Nancy Moureau argues that a major source of infection remains dangerously exposed. In an upcoming presentation at the INS conference, Dr. Moureau will address what she calls the “gross gap in protection”—the contamination that occurs on IV line connectors and hubs through environmental exposure and routine clinical handling.

These external access points, which are frequently touched, disconnected, and reconnected, can become colonized by dangerous pathogens. Without adequate protection, these microbes can gain direct entry into a patient's bloodstream, bypassing the protections at the skin insertion site and leading to a devastating CABSI.

Innovating at the Point of Contamination

In response to this challenge, Covalon is championing a strategy of total line protection. The company will be showcasing two key innovations at the INS meeting designed to seal this gap: VALGuard and CovaClear.

VALGuard is a sterile, single-use device that creates a transparent, protective shell around IV line connections and catheter hubs. By providing a physical barrier, it shields these critical access points from external contaminants like bodily fluids, airborne particles, and direct touch. While the company carefully notes that VALGuard is not yet cleared by the U.S. Food and Drug Administration (FDA) specifically for infection prevention, its role as a barrier to gross contamination is gaining significant clinical attention.

A recent peer-reviewed study conducted at the Children's Hospital at Montefiore provided compelling real-world evidence. The pre-post intervention study, published in the Journal of the Association for Vascular Access, found that implementing VALGuard as part of an infection prevention bundle led to a dramatic 78% reduction in hospital-wide CLABSI rates. In the Pediatric Critical Care Unit (PCCU), where compliance was highest, the results were even more striking: a 100% reduction, with the CLABSI rate dropping from 1.8 per 1,000 line days to zero in the 16 months following implementation.

Complementing this is CovaClear, an IV cover dressing designed to shield the primary dressing at the insertion site. Its purpose is to prevent contamination that could lead to costly and risky unplanned dressing changes, thereby reducing resource use and protecting the integrity of the primary sterile barrier.

Empowering Nurses on the Frontline

The burden of preventing these infections falls heavily on frontline clinicians, particularly nurses who manage IV lines daily. The constant vigilance required to maintain sterility across multiple patient interactions is immense, and the consequences of a single lapse can be severe.

“Clinical care staff are on the front lines of patient safety, and they carry the emotional weight of every outcome,” said Brent Ashton, Covalon’s Chief Executive Officer, in a statement. “Complications such as infections have tragic consequences for patients, clinicians and hospitals or other sites of care, but fortunately, they are largely preventable.”

By providing simple, effective tools, the company aims to empower these clinicians. The goal is to integrate contamination protection into the standard workflow, making it easier to adhere to best practices without adding significant time or complexity to patient care. This approach recognizes that the most effective solutions are those that seamlessly support, rather than disrupt, the demanding work of healthcare professionals.

A Niche Focus in a Crowded Field

The global IV dressing market, valued at over $830 million and projected to exceed $1.3 billion by 2032, is dominated by medical giants like 3M, BD, and Cardinal Health. In this competitive landscape, Covalon is carving out a distinct niche by focusing intently on the vulnerabilities beyond the insertion site.

While major players have perfected transparent dressings and antimicrobial coatings for the catheter site itself, Covalon’s strategy addresses the dynamic and exposed nature of the IV tubing and connectors. This targeted approach is gaining traction as healthcare systems look for comprehensive solutions to drive their hospital-acquired infection rates toward zero.

As clinicians and industry leaders gather in Louisville, the focus on this “gross gap” signals a potential shift in infection control paradigms. The conversation is expanding from simply protecting the insertion point to securing the entire vascular access line. For the thousands of patients who rely on these lifelines every day, closing this gap cannot happen soon enough.